Clinical and Preclinical Publications

Final Analysis of A Randomized, Double Blind, Phase 2 Study of Sorafenib With or Without YIV-906 in Patients With Advanced HCC

European Society For Medical Oncology (ESMO) Gastrointestinal Cancers Congress, July 2025

International phase II randomized placebo-controlled study investigating the combination of YIV-906 plus sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma

American Society of Clinical Oncology (ASCO), May 2025

A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer

Journal of Gastrointestinal Oncology, July 2024

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy

Frontiers in Pharmacology, October 2023

YIV-818-A enhanced apalutamide, darolutamide and enzalutamide action for prostate cancer treatment by down-regulating androgen receptor protein, inhibiting glucocorticoid receptor function and epigenetic regulation

American Association for Cancer Research (AACR), April 2023

YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity

Frontiers in Pharmacology, January 2023

Preclinical Immunotherapy Research Featured in Poster Presentation at AACR 2022 Annual Meeting Highlights YIV-906’s Immunomodulatory Mechanisms in Combination with Immune Checkpoint or CAR T Therapy
American Association for Cancer Research, April 2022
AACR Abstract
AACR Poster

A Phase II Clinical Trial on the Combination Therapy of YIV-906 (PHY906) Plus Capecitabine in Hepatocellular Carcinoma
The Oncologist, March 2021

Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China
Frontiers in Pharmacology, February 2021

A phase II randomized placebo-controlled study of YIV-906 and sorafenib in Hepatitis B positive (HBV+) patients with advanced hepatocellular carcinoma (HCC), Journal of Clinical Oncology
American Society of Clinical Oncology (ASCO), February 2020

The Evolution of Future Medicine – WE Medicine – To Meet Unmet Medical Needs
Novel Approaches in Cancer Study, November 2019

YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy (Anti-PD1) against liver cancer by changing the tumor micro-environment associated with M1 macrophages infiltration
American Association for Cancer Research (AACR), July 2019

Mechanism Based Quality Control (Mech QC) of Herbal Products- A Case Study YIV-906 (PHY906)
Frontiers in Pharmacology, November 2018

YIV-906 (PHY906) enhanced the anti-tumor activity of immune checkpoint blockade therapy: Anti-PD-1 against liver cancer
American Association for Cancer Research (AACR), July 2018

STAR Discovery Platform – Majority of Chinese Medicine Herb Category QingReYao Have Multiple Mechanisms of Anti-Inflammatory Activity
Scientific Reports, May 2018

Wedding Rigorous Scientific Methodology and Ancient Herbal Wisdom to Benefit Cancer Patients: The Development of YIV-906 (PHY906)
CancerNetwork – Oncology Journal, February 2018

Pilot trial of YIV-906 with neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced rectal cancer
Annals of Oncology, June 2018

Pilot trial of YIV-906 (KD018) with neo-adjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
American Society of Clinical Oncology (ASCO), June 2017

YIV-906 (PHY906, KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
Scientific Reports, March 2015

The Art and Science of Traditional Medicine – Lessons from the Development of the Chinese Formula YIV-906 (PHY906)
Science, January 2015

The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine YIV-906 (PHY906, KD018)
BMC Complementary and Alternative Medicine, July 2014

First-in-human Phase II trial of the Botanical Formulation YIV-906 (PHY906) with Capecitabine as Second-line Therapy in Patients with Advanced Pancreatic Cancer
Cancer Chemotherapy Pharmacology, February 2014

Preclinical Studies of the Chinese Herbal Medicine formulation YIV-906 (PHY906) as a Potential Adjunct to Radiation Therapy
International Journal of Radiation Biology, January 2013

Evidence-based Anticancer Materia Medica for Pancreatic Cancer
from Chapter 11 – Evidence-based Anti-cancer Complementary and Alternative Medicine: Herbal Medicine for Various Cancers, Springer, 2012

Interaction of a traditional Chinese Medicine YIV-906 (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment
BMC Medical Genomics, May 2011

A Phase I Study of the Chinese Herbal Medicine YIV-906 (PHY906) as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer
Clinical Colorectal Cancer, August 2010

The Four Herb Chinese Medicine YIV-906 (PHY906) Reduces Chemotherapy Induced Gastrointestinal Toxicity
Science Translational Medicine, August 2010

Any Second-Line Therapy for Advanced Pancreatic Cancer? Highlights from the “2010 ASCO Gastrointestinal Cancers Symposium”
Journal of the Pancreas, March 2010

Phase II study of YIV-906 (PHY906) plus capecitabine in patients with gemcitabine-refractory pancreatic cancer and measurement of cytokines
American Society of Clinical Oncology (ASCO), May 2010

Phase I study of the botanical formulation YIV-906 (PHY906) with capecitabine in advanced pancreatic and other gastrointestinal malignancies
Phytomedicine, March 2010

Phase I/II Study of YIV-906 (PHY906) plus Capecitabine in Advanced Hepatocellular Carcinoma
Anticancer Research, October 2009

Exploration of the mechanisms of YIV-906 (PHY906) in reducing the intestinal toxicity caused by irinotecan
American Association for Cancer Research (AACR), April 2009

Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the “44th ASCO Annual Meeting”
Journal of the Pancreas, July 2008

A phase I/II study of YIV-906 (PHY906) plus capecitabine in patients with advanced pancreatic cancer
American Society of Clinical Oncology (ASCO), May 2008

YIV-906 (PHY906) in hepatocellular carcinoma
American Association for Cancer Research (AACR), May 2007

YIV-906 (PHY906) as a broad-spectrum enhancer in cancer therapy: Clinical and preclinical results in hepatocellular carcinoma
American Association for Cancer Research (AACR), April 2006

Developing YIV-906 (PHY906) as a broad- spectrum modulator of chemotherapeutic agents in cancer therapy
American Association for Cancer Research (AACR), April 2004

Definition of Chinese herbal formulation YIV-906 (PHY906)
National Cancer Institute (NCI) Drug Dictionary